Evogene (NASDAQ:EVGN) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a research report sent to investors on Tuesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Alliance Global Partners reaffirmed a “buy” rating on shares of Evogene in a research note on Friday, March 7th.

Evogene Stock Performance

NASDAQ:EVGN opened at $1.43 on Tuesday. The firm’s fifty day moving average is $1.52 and its 200-day moving average is $1.93. Evogene has a 52 week low of $1.20 and a 52 week high of $9.00. The firm has a market cap of $7.67 million, a P/E ratio of -0.32 and a beta of 1.28.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.78. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%. The company had revenue of $1.61 million for the quarter, compared to analyst estimates of $3.63 million. During the same period in the prior year, the firm posted ($1.30) EPS.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evogene stock. Citadel Advisors LLC acquired a new position in shares of Evogene Ltd. (NASDAQ:EVGN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned about 0.30% of Evogene at the end of the most recent quarter. 10.40% of the stock is currently owned by hedge funds and other institutional investors.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.